N Ott1, H Geddert, M Sarbia. 1. Department of Pathology, Unfallkrankenhaus Berlin, Warener Strasse 7, 12683 Berlin, Germany.
Abstract
PURPOSE: Folate deficiency is considered to increase the risk for the development of malignant tumors such as prostate and colorectal cancer. Methionine synthase (MTR) and cystathionine ss-synthase (CBS) are enzymes that play a central role in folate metabolism, thereby affecting DNA methylation and synthesis. A single A-->G substitution at nucleotide 2756 of the MTR and a 68 bp CBS insertion polymorphism in exon 8 have been associated with decreased enzyme activity. The purpose of this study is to compare the association of the MTR A2756G polymorphism and CBS insertion polymorphism with susceptibility to carcinomas of the upper gastrointestinal tract. METHODS: Using the restriction fragment length polymorphism (RFLP)-PCR, the prevalence of MTR A2756G and CBS insertion polymorphism was determined in healthy controls (n = 257) and in patients with esophageal squamous cell carcinoma (ESCC) (n = 263), Barrett's esophagus-associated esophageal adenocarcinoma (BC) (n = 89), cardiac carcinoma (CC) (n = 144), or gastric carcinoma (GC) (n = 221) from German Caucasian subjects. RESULTS: No significant difference in MTR A2756G genotype distribution was observed between controls (A/A 66.9%, A/G 29.8%, G/G 3.3%) and patients with ESCC (A/A 61.7%, A/G 36.3%, G/G 2.1%), BC (A/A 69.2%, A/G 26.9%, G/G 3.9%), CC (A/A 51.8%, A/G 44.6%, G/G 3.6%), or GC (A/A 73.4%, A/G 20.9%, G/G 5.7%). Similarly, the CBS genotype (I: allele with 68 bp insertion; N: allele without insertion) distribution among German patients with ESCC (N/N 86.8%, I/N 13.2%), BC (N/N 90.2%, I/N 9.8%), CC (N/N 90.1%, I/N 9.9%) or GC (N/N 91.3%, I/N 8.7%) was not different from healthy controls (N/N 90.4%, I/N 9.6%). The gene allele constellation I/I was not present. CONCLUSIONS: The current study suggests that there is no association between MTR A2756G polymorphism and the CBS (844ins68) insertion polymorphism and cancer of the upper gastrointestinal tract.
PURPOSE:Folate deficiency is considered to increase the risk for the development of malignant tumors such as prostate and colorectal cancer. Methionine synthase (MTR) and cystathionine ss-synthase (CBS) are enzymes that play a central role in folate metabolism, thereby affecting DNA methylation and synthesis. A single A-->G substitution at nucleotide 2756 of the MTR and a 68 bp CBS insertion polymorphism in exon 8 have been associated with decreased enzyme activity. The purpose of this study is to compare the association of the MTR A2756G polymorphism and CBS insertion polymorphism with susceptibility to carcinomas of the upper gastrointestinal tract. METHODS: Using the restriction fragment length polymorphism (RFLP)-PCR, the prevalence of MTR A2756G and CBS insertion polymorphism was determined in healthy controls (n = 257) and in patients with esophageal squamous cell carcinoma (ESCC) (n = 263), Barrett's esophagus-associated esophageal adenocarcinoma (BC) (n = 89), cardiac carcinoma (CC) (n = 144), or gastric carcinoma (GC) (n = 221) from German Caucasian subjects. RESULTS: No significant difference in MTR A2756G genotype distribution was observed between controls (A/A 66.9%, A/G 29.8%, G/G 3.3%) and patients with ESCC (A/A 61.7%, A/G 36.3%, G/G 2.1%), BC (A/A 69.2%, A/G 26.9%, G/G 3.9%), CC (A/A 51.8%, A/G 44.6%, G/G 3.6%), or GC (A/A 73.4%, A/G 20.9%, G/G 5.7%). Similarly, the CBS genotype (I: allele with 68 bp insertion; N: allele without insertion) distribution among German patients with ESCC (N/N 86.8%, I/N 13.2%), BC (N/N 90.2%, I/N 9.8%), CC (N/N 90.1%, I/N 9.9%) or GC (N/N 91.3%, I/N 8.7%) was not different from healthy controls (N/N 90.4%, I/N 9.6%). The gene allele constellation I/I was not present. CONCLUSIONS: The current study suggests that there is no association between MTR A2756G polymorphism and the CBS (844ins68) insertion polymorphism and cancer of the upper gastrointestinal tract.
Authors: S T Mayne; H A Risch; R Dubrow; W H Chow; M D Gammon; T L Vaughan; D C Farrow; J B Schoenberg; J L Stanford; H Ahsan; A B West; H Rotterdam; W J Blot; J F Fraumeni Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-10 Impact factor: 4.254
Authors: Jianhui Zhang; Rainer B Zotz; Yan Li; Rui Wang; Sybille Kiel; Wolfgang A Schulz; Denggui Wen; Zhifeng Chen; Liwei Zhang; Shijie Wang; Helmut E Gabbert; Mario Sarbia Journal: J Cancer Res Clin Oncol Date: 2004-07-29 Impact factor: 4.553
Authors: Torukiri I Ibiebele; Maria Celia Hughes; Nirmala Pandeya; Zhen Zhao; Grant Montgomery; Nick Hayward; Adèle C Green; David C Whiteman; Penelope M Webb Journal: J Nutr Date: 2010-12-22 Impact factor: 4.798
Authors: Simone J P M Eussen; Stein Emil Vollset; Steinar Hustad; Øivind Midttun; Klaus Meyer; Ase Fredriksen; Per Magne Ueland; Mazda Jenab; Nadia Slimani; Paolo Boffetta; Kim Overvad; Ole Thorlacius-Ussing; Anne Tjønneland; Anja Olsen; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Sophie Morois; Cornelia Weikert; Tobias Pischon; Jakob Linseisen; Rudolf Kaaks; Antonia Trichopoulou; Demosthenes Zilis; Michael Katsoulis; Domenico Palli; Valeria Pala; Paolo Vineis; Rosario Tumino; Salvatore Panico; Petra H M Peeters; H Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; Guri Skeie; Xavier Muñoz; Carmen Martínez; Miren Dorronsoro; Eva Ardanaz; Carmen Navarro; Laudina Rodríguez; Bethany VanGuelpen; Richard Palmqvist; Jonas Manjer; Ulrika Ericson; Sheila Bingham; Kay-Tee Khaw; Teresa Norat; Elio Riboli Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-02 Impact factor: 4.254
Authors: Catherine Metayer; Ghislaine Scélo; Anand P Chokkalingam; Lisa F Barcellos; Melinda C Aldrich; Jeffrey S Chang; Neela Guha; Kevin Y Urayama; Helen M Hansen; Gladys Block; Vincent Kiley; John K Wiencke; Joseph L Wiemels; Patricia A Buffler Journal: Cancer Causes Control Date: 2011-07-12 Impact factor: 2.506
Authors: Ana L S Galbiatti; Mariangela T Ruiz; Luis S Raposo; José V Maniglia; Erika C Pavarino-Bertelli; Eny M Goloni-Bertollo Journal: Arch Med Sci Date: 2010-10-26 Impact factor: 3.318
Authors: Xiayu Wu; Tianning Zou; Neng Cao; Juan Ni; Weijiang Xu; Tao Zhou; Xu Wang Journal: Hered Cancer Clin Pract Date: 2014-02-21 Impact factor: 2.857